Drug Selectivity (eBook)

Norbert Handler holds a PhD in Medicinal Chemistry from the University of Vienna, where he worked for several years as a postdoc scientist in the field of Medicinal Chemistry. He received an Erwin-Schrödinger-Scholarship and moved to ETH Zürich where he joined Professor Schubigers Group at the Center of Radiopharmaceutical Sciences. After his return to Vienna, he managed the technology transfer office at the University of Vienna before he joined Savira pharmaceuticals, Vienna, as Head of Drug Discovery and Development. Together with Helmut Buschmann he founded RD&C Research, Development & Consulting in Vienna, where he currently is working as Managing Partner. He contributed to more than 25 scientific papers and several patent applications. Helmut Buschmann has a PhD in organic chemistry from Aachen University and extensive industrial experience in medicinal chemistry, drug discovery and development, scale-up, pharmaceutical development, CMC, patent filing and prosecution. Helmut has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors, both in industry and academia. During his career he worked with a broad range of different targets in different therapeutic areas from pain research to anti-infectives. He has a long publication and patent record, being an author/co-author in more than 150 scientific publications, editor of various reference books and is a named inventor/co-inventor in more than 250 patent applications. As a result of his research activities more than 15 NCEs within different therapeutic areas have entered the clinical phase (e.g. Rosonabant, Cizorlitine, Dulopetine, Axamadol,). Some of them have reached clinical phase III or are marketed (e.g. Tapentadol: Nucynta® Palexia®). Currently, he is Head of Chemistry, Pharmaceutical Development and Patent A_ airs at AiCuris, Wuppertal and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.

PART I. INTRODUCTION
Polypharmacology in Drug Discovery

PART II. SELECTIVITY OF MARKTETED DRUGS
Kinase Inhibitors
New Indications for Marketed Drugs
Discovery Technologies of New Indications

PART III. FIXED-DOSE COMBINATIONS
The Growing Market of Fixed-Dose Combinations

PART IV. UNSELECTIVE DRUGS IN DRUG DISCOVERY
The Growing Importance of Individualising Drugs
Drug Discovery Strategies for the Generation of Multi-Target Ligands against Neglected Tropical Diseases
Designing-In Approach
The Linker Approach (Drug-Conjugates)
Merged Multiple Ligands
Pharmacophore Generation of Multiple Ligands
Cellular Assays

PART V. THERAPEUTIC AREAS FOR DESIGNED MULTIPLE LIGANDS
5HT Transporter-Based Multiple Ligands for Depression
Multiple Ligands Targeting the Angiotensin System for Hypertension
PPAR-Based Multiple Ligands for Metabolic Disease
Antibiotics
Multiple Ligands in Cancer Therapy
Multiple Ligands in Neurodegenerative Diseases